Trial Profile
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid in Adults with Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms onset 5
- Sponsors Novo Nordisk
- 22 Oct 2019 According to a Novo Nordisk media release, based on the data from this clinical trial (onset 5) the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes.
- 26 Jul 2017 Status changed from active, no longer recruiting to completed.
- 26 Jan 2017 Status changed from recruiting to active, no longer recruiting.